Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

Background CombiRx was a randomized, double-blind, placebo-controlled phase 3 trial in treatment-naive relapsing-remitting multiple sclerosis (RRMS) patients randomized to intramuscular interferon beta-1a (IM IFN beta-1a), glatiramer acetate (GA), or both therapies. Objective This analysis investiga...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Gary Cutter, Richard A Rudick, Carl de Moor, Carol M Singh, Elizabeth Fisher, Thijs Koster, Fred D Lublin, Jerry S Wolinsky, Henry McFarland, Steven Jacobson, Maria L Naylor
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	SAGE Publishing 2023-04-01
Cyfres:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Mynediad Ar-lein:	https://doi.org/10.1177/20552173231169463
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!